Published in PLoS One on September 18, 2008
The regulation of p53 by phosphorylation: a model for how distinct signals integrate into the p53 pathway. Aging (Albany NY) (2009) 1.12
Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. Carcinogenesis (2015) 0.95
Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53. Br J Cancer (2010) 0.91
Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models. PLoS One (2010) 0.87
Cellular senescence as a target in cancer control. J Aging Res (2010) 0.85
Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA. Oncotarget (2015) 0.82
Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa. Br J Cancer (2010) 0.81
Modeling a new water channel that allows SET9 to dimethylate p53. PLoS One (2011) 0.80
Disruptive chemicals, senescence and immortality. Carcinogenesis (2015) 0.78
Phosphorylation of gH2AX as a novel prognostic biomarker for laryngoesophageal dysfunction-free survival. Oncotarget (2016) 0.77
A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A (1995) 32.89
p53, the cellular gatekeeper for growth and division. Cell (1997) 31.04
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell (1997) 29.13
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell (1993) 12.02
Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell (2003) 11.40
A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell (2006) 11.01
The RB and p53 pathways in cancer. Cancer Cell (2002) 8.02
Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell (1990) 6.37
Modeling the therapeutic efficacy of p53 restoration in tumors. Cell (2006) 5.95
p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell (2000) 5.64
Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev (1998) 5.60
Decision making by p53: life, death and cancer. Cell Death Differ (2003) 5.52
Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev (2000) 5.04
PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature (2000) 4.90
p19ARF links the tumour suppressor p53 to Ras. Nature (1998) 4.89
p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev (1996) 3.98
The complexity of p53 stabilization and activation. Cell Death Differ (2006) 3.61
Oncogene-induced cell senescence--halting on the road to cancer. N Engl J Med (2006) 3.39
PML is induced by oncogenic ras and promotes premature senescence. Genes Dev (2000) 3.35
p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev (2000) 2.74
Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res (2005) 2.67
Oncogenic ras and p53 cooperate to induce cellular senescence. Mol Cell Biol (2002) 2.61
A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization. Genes Dev (2006) 2.41
The cellular response to p53: the decision between life and death. Oncogene (1999) 2.31
p53: guardian of the genome and policeman of the oncogenes. Cell Cycle (2007) 2.23
Temporal dissection of p53 function in vitro and in vivo. Nat Genet (2005) 2.19
Lats2/Kpm is required for embryonic development, proliferation control and genomic integrity. EMBO J (2004) 2.18
Tumor suppressors and oncogenes in cellular senescence. Exp Gerontol (2000) 2.17
Functional activation of p53 via phosphorylation following DNA damage by UV but not gamma radiation. Proc Natl Acad Sci U S A (1998) 2.11
Suppressing cancer: the importance of being senescent. Science (2005) 2.03
Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage. Nature (1996) 1.98
Tumour biology: Policing of oncogene activity by p53. Nature (2006) 1.86
Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation. Proc Natl Acad Sci U S A (2001) 1.79
PML NBs associate with the hMre11 complex and p53 at sites of irradiation induced DNA damage. Oncogene (2002) 1.77
Ultraviolet radiation, but not gamma radiation or etoposide-induced DNA damage, results in the phosphorylation of the murine p53 protein at serine-389. Proc Natl Acad Sci U S A (1998) 1.70
From G0 to S phase: a view of the roles played by the retinoblastoma (Rb) family members in the Rb-E2F pathway. J Cell Biochem (2007) 1.65
Posttranslational modifications of p53 in replicative senescence overlapping but distinct from those induced by DNA damage. Mol Cell Biol (2000) 1.46
The retinoblastoma tumor-suppressor gene, the exception that proves the rule. Oncogene (2006) 1.41
Regulation of cell cycle progression and nuclear affinity of the retinoblastoma protein by protein phosphatases. Proc Natl Acad Sci U S A (1993) 1.38
Regulation and function of the p53-related proteins: same family, different rules. Trends Cell Biol (2000) 1.27
Protein phosphatase 1alpha is a Ras-activated Bad phosphatase that regulates interleukin-2 deprivation-induced apoptosis. EMBO J (2000) 1.20
Downregulation of the large tumor suppressor 2 (LATS2/KPM) gene is associated with poor prognosis in acute lymphoblastic leukemia. Leukemia (2005) 1.19
Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. EMBO J (2004) 1.16
Constitutively active protein phosphatase 1alpha causes Rb-dependent G1 arrest in human cancer cells. Curr Biol (1997) 1.11
Tumour suppressor p53 down-regulates the expression of the human hepatocyte nuclear factor 4alpha (HNF4alpha) gene. Biochem J (2006) 1.09
The senescent side of tumor suppression. Cell Cycle (2005) 1.08
High molecular weight protein phosphatase type 1 dephosphorylates the retinoblastoma protein. J Biol Chem (1997) 1.05
Ras mutation, irrespective of cell type and p53 status, determines a cell's destiny to undergo apoptosis by okadaic acid, an inhibitor of protein phosphatase 1 and 2A. Mol Pharmacol (1999) 1.00
Loss-of-function genetics in mammalian cells: the p53 tumor suppressor model. Nucleic Acids Res (2000) 0.93
PPP1CA contributes to the senescence program induced by oncogenic Ras. Carcinogenesis (2008) 0.92
Of mice without pockets: mouse models to study the function of Rb family proteins. Front Biosci (2007) 0.88
Protein phosphatase type 1, the product of the retinoblastoma susceptibility gene, and cell cycle control. Front Biosci (1998) 0.87
Cellular senescence induced by p53-ras cooperation is independent of p21waf1 in murine embryo fibroblasts. J Cell Biochem (2004) 0.86
Oncogene-dependent tumor suppression: using the dark side of the force for cancer therapy. Cold Spring Harb Symp Quant Biol (2005) 0.82
Threshold level of p53 required for the induction of apoptosis in X-irradiated MOLT-4 cells. Int J Radiat Oncol Biol Phys (2007) 0.76
Glycolytic enzymes can modulate cellular life span. Cancer Res (2005) 3.78
The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets (2008) 3.36
PTEN, more than the AKT pathway. Carcinogenesis (2007) 2.70
Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem (2005) 2.31
RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis. Cancer Res (2012) 1.98
Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol (2013) 1.84
CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus. Oncogene (2005) 1.63
Spinophilin acts as a tumor suppressor by regulating Rb phosphorylation. Cell Cycle (2011) 1.53
Spinophilin loss contributes to tumorigenesis in vivo. Cell Cycle (2011) 1.45
Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients. Mol Cancer Ther (2005) 1.32
Pim kinases in cancer: diagnostic, prognostic and treatment opportunities. Biochem Pharmacol (2012) 1.31
Immortalization of primary human prostate epithelial cells by c-Myc. Cancer Res (2005) 1.30
Cold-inducible RNA-binding protein bypasses replicative senescence in primary cells through extracellular signal-regulated kinase 1 and 2 activation. Mol Cell Biol (2009) 1.20
The PIM family of serine/threonine kinases in cancer. Med Res Rev (2013) 1.17
Cell cycle deregulation: a common motif in cancer. Prog Cell Cycle Res (2003) 1.14
Membrane localization of all class I PI 3-kinase isoforms suppresses c-Myc-induced apoptosis in Rat1 fibroblasts via Akt. J Cell Biochem (2005) 1.04
Epithelial-to-mesenchymal transition and stem cells in endometrial cancer. Hum Pathol (2013) 1.03
Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer. Carcinogenesis (2006) 1.03
Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases. J Biol Chem (2009) 1.03
Understanding FOXO, new views on old transcription factors. Curr Cancer Drug Targets (2010) 1.01
Activation of phosphatidylinositol 3-kinase by membrane localization of p110alpha predisposes mammary glands to neoplastic transformation. Cancer Res (2008) 0.97
Chemical genetic analysis of FOXO nuclear-cytoplasmic shuttling by using image-based cell screening. Chembiochem (2008) 0.97
Cooperation between Cdk4 and p27kip1 in tumor development: a preclinical model to evaluate cell cycle inhibitors with therapeutic activity. Cancer Res (2005) 0.96
A regularized method for selecting nested groups of relevant genes from microarray data. J Comput Biol (2009) 0.96
An HTS approach to screen for antagonists of the nuclear export machinery using high content cell-based assays. Assay Drug Dev Technol (2007) 0.95
Mitotic catastrophe cell death induced by heat shock protein 90 inhibitor in BRCA1-deficient breast cancer cell lines. Mol Cancer Ther (2008) 0.94
Levels of p27(kip1) determine Aplidin sensitivity. Mol Cancer Ther (2007) 0.94
Novel UBE3A mutations causing Angelman syndrome: different parental origin for single nucleotide changes and multiple nucleotide deletions or insertions. Am J Med Genet A (2009) 0.93
MAP17 enhances the malignant behavior of tumor cells through ROS increase. Carcinogenesis (2007) 0.93
Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition. Cancer Lett (2010) 0.93
MAP17 overexpression is a common characteristic of carcinomas. Carcinogenesis (2007) 0.92
DNA methylation signatures identify biologically distinct thyroid cancer subtypes. J Clin Endocrinol Metab (2013) 0.92
PPP1CA contributes to the senescence program induced by oncogenic Ras. Carcinogenesis (2008) 0.92
Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. J Cell Biochem (2007) 0.91
Association between the miRNA signatures in plasma and bronchoalveolar fluid in respiratory pathologies. Dis Markers (2012) 0.90
Down-regulation of spinophilin in lung tumours contributes to tumourigenesis. J Pathol (2011) 0.89
Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas. Blood (2007) 0.87
Loss-of-function genetic screening identifies a cluster of ribosomal proteins regulating p53 function. Carcinogenesis (2008) 0.87
Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models. PLoS One (2010) 0.87
MAP17 and SGLT1 protein expression levels as prognostic markers for cervical tumor patient survival. PLoS One (2013) 0.86
The TGF-beta co-receptor endoglin modulates the expression and transforming potential of H-Ras. Carcinogenesis (2010) 0.86
Spinophilin loss correlates with poor patient prognosis in advanced stages of colon carcinoma. Clin Cancer Res (2013) 0.86
The essential role of PIM kinases in sarcoma growth and bone invasion. Carcinogenesis (2012) 0.86
Using multiplexed regulation of luciferase activity and GFP translocation to screen for FOXO modulators. BMC Cell Biol (2009) 0.86
Cellular senescence induced by p53-ras cooperation is independent of p21waf1 in murine embryo fibroblasts. J Cell Biochem (2004) 0.86
MAP17 inhibits Myc-induced apoptosis through PI3K/AKT pathway activation. Carcinogenesis (2007) 0.86
Cellular senescence as a target in cancer control. J Aging Res (2010) 0.85
Genetic modelling of the PTEN/AKT pathway in cancer research. Clin Transl Oncol (2008) 0.85
Overexpression of cyclin D1 inhibits TNF-induced growth arrest. J Cell Biochem (2003) 0.85
Influence of amine ligands on the aquation and cytotoxicity of trans-diamine platinum(II) anticancer complexes. Dalton Trans (2009) 0.84
Inhibition of phosphatidylinositol-3-kinase synergizes with gemcitabine in low-passage tumor cell lines correlating with Bax translocation to the mitochondria. Anticancer Drugs (2005) 0.84
Mouse models to decipher the PI3K signaling network in human cancer. Curr Mol Med (2009) 0.84
Anamnestic immune response in 3- to 4-year-old children previously immunized with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine as 2-dose or 3-dose priming and a booster dose in the first year of life. Pediatr Infect Dis J (2011) 0.84
A dual-color fluorescence-based platform to identify selective inhibitors of Akt signaling. PLoS One (2008) 0.83
The preparation and characterization of trans-platinum(IV) complexes with unusually high cytotoxicity. Dalton Trans (2010) 0.83
Identification of oxidative stress related proteins as biomarkers for lung cancer and chronic obstructive pulmonary disease in bronchoalveolar lavage. Int J Mol Sci (2013) 0.82
Inhibiting PI3K as a therapeutic strategy against cancer. Clin Transl Oncol (2009) 0.82
Targeting of p53-transcriptional dysfunction by conditionally replicating adenovirus is not limited by p53-homologues. Mol Ther (2009) 0.81
PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome. BMC Cancer (2012) 0.81
The role of p53 in the cellular toxicity by active trans-platinum complexes containing isopropylamine and hydroxymethylpyridine. Eur J Med Chem (2009) 0.80
Using cells devoid of RAS proteins as tools for drug discovery. Mol Carcinog (2009) 0.79
Structure-activity relationship of new trans-platinum(II) and (IV) complexes with cyclohexylamine. Interference with cell cycle progression and induction of cell death. J Inorg Biochem (2006) 0.79
Bypassing cellular senescence by genetic screening tools. Clin Transl Oncol (2010) 0.78
Conditional transgenic expression of PIM1 kinase in prostate induces inflammation-dependent neoplasia. PLoS One (2013) 0.78
MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer. BMC Cancer (2014) 0.77
New trans-platinum drugs with phosphines and amines as carrier ligands induce apoptosis in tumor cells resistant to cisplatin. J Med Chem (2007) 0.77
Mst1, RanBP2 and eIF4G are new markers for in vivo PI3K activation in murine and human prostate. Carcinogenesis (2007) 0.77
Cancer, senescence, and aging: translation from basic research to clinics. J Aging Res (2011) 0.76
EMX homeobox genes regulate microphthalmia and alter melanocyte biology. Exp Cell Res (2005) 0.76
Effectiveness of the Ten-valent Pneumococcal Conjugate Vaccine Against Tympanostomy Tube Placements in a Cluster-randomized Trial. Pediatr Infect Dis J (2015) 0.76
Battling cancer on many fronts. Meeting on New Battlefields in Human Cancer--Attacking in Many Fronts. EMBO Rep (2008) 0.75
Duplication of the Williams-Beuren critical region: case report and further delineation of the phenotypic spectrum. BMJ Case Rep (2009) 0.75
Correction: Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src. Oncotarget (2016) 0.75
Non-neutral role of replicative senescence in tissue homeostasis and tumorigenesis. J Theor Biol (2004) 0.75
Oxidation of anticancer Pt(II) complexes with monodentate phosphane ligands: towards stable but active Pt(IV) prodrugs. Chem Commun (Camb) (2013) 0.75
Adding more content to screening: reactivation of FOXO as a therapeutic strategy. Clin Transl Oncol (2009) 0.75
Between bench and bed side: PI3K inhibitors. Curr Mol Pharmacol (2010) 0.75
Influence of (hydroxymethyl)pyridine and pyridine-carboxylic acids, in trans-position to the isopropylamine and amine ligands, on the cytotoxicity of platinum complexes. Chem Biodivers (2008) 0.75
Targeted search for anticancer drugs--CNIO cancer conference. 16-18 March, Madrid, Spain. IDrugs (2003) 0.75
The second generation of iodido complexes: trans-[PtI2(amine)(amine')] bearing different aliphatic amines. J Inorg Biochem (2013) 0.75
Identification of transcripts specific for physiological gene activation by platelet-derived growth factor (PDGF)-B in intact brain tissue. J Cell Biochem (2005) 0.75